Immune System News and Research

RSS

Interaction between fat cells and bacterial toxins can lead to chronic inflammation

Making fat cells immortal might seem like a bad idea to most people, but for a team of University of Iowa scientists it was the ideal way to study how the interaction between bacteria and fat cells might contribute to diabetes.

31 Oct 2013

New finding could help lead to better treatments for eczema

For the millions of people suffering from the intensely red, horribly itchy skin condition known as eczema, the only thing more maddening than their disease is the lack of understanding of what causes it, or makes it flare up from time to time.

31 Oct 2013

Scientists unravel the major cause of protein citrullination in rheumatoid arthritis

Experiments by scientists at Johns Hopkins and in Boston have unraveled two biological mechanisms as the major cause of protein citrullination in rheumatoid arthritis. Protein citrullination is suspected of sparking the immune system and driving the cascade of events leading to the disease.

31 Oct 2013

Early stem cell transplants does not improve overall survival in non-Hodgkin's lymphoma patients

Performing early stem cell transplants in patients with aggressive non-Hodgkin's lymphoma does not improve overall survival in high-risk patients, according to a study published in the New England Journal of Medicine.

31 Oct 2013

New insights into human cytomegalovirus may lead to development of therapeutic interventions

New insights into how human cytomegalovirus, the leading cause of birth defects associated with infection spreads from pregnant mother to fetus and from organ to organ in newborns provides translational researchers an exciting new avenue for investigation that may lead to the development of therapeutic interventions.

31 Oct 2013

CytoDyn submits protocol to FDA for Phase IIb clinical trial of PRO 140

CytoDyn Inc. ("CytoDyn") (OTCQB:CYDY), a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses, today announced that CytoDyn Chief Medical Officer David Feigal, M.D., has submitted a revised protocol to the U.S. Food and Drug Administration relating to an upcoming Phase IIb clinical trial of PRO 140, CytoDyn's leading product under development as a treatment for Human Immunodeficiency Virus (HIV) infection.

31 Oct 2013

UofL researcher enters into license and research collaboration agreement with Novartis

The University of Louisville today announced that researcher Dr. Suzanne Ildstad, representing Regenerex LLC, has entered into a license and research collaboration agreement with Novartis to provide access to stem cell technology that has the potential to help transplant patients avoid taking anti-rejection medicine for life and could serve as a platform for treatment of other diseases.

31 Oct 2013

Immune Design closes Series C financing totalling up to $49M

Immune Design, a biotechnology company focused on the development of novel immune-based therapies for cancer and other chronic conditions, today announced it has closed a Series C financing totalling up to $49 million.

30 Oct 2013

Researchers overcome obstacle to using viruses to deliver therapeutic genes

Scientists in The Research Institute at Nationwide Children's Hospital have found a way to overcome one of the biggest obstacles to using viruses to deliver therapeutic genes: how to keep the immune system from neutralizing the virus before it can deliver its genetic payload. In a study published recently in Molecular Therapy, researchers found that giving subjects a treatment to temporarily rid the body of antibodies provides the virus safe passage to targeted cells, allowing it to release a corrective or replacement gene to treat disease.

30 Oct 2013

Promising melanoma drug demonstrates potential for non-small cell lung cancer treatment

An experimental new cancer drug called MK-3475, which has shown dramatic promise for treating melanoma is also showing early potential as an effective treatment for patients with non-small cell lung cancer, the leading cause of cancer death of men and women worldwide.

30 Oct 2013

New DNA vaccine effective against plaques in mouse model of Alzheimer's disease

Amyloid-beta (Aβ) active immunization in Alzheimer's disease can increase the rate of Aβ clearance, and delay cognitive dysfunction, but it is easy to induce meningoencephalitis, which may be related to activation of Th1 lymphocytes.

30 Oct 2013

Mice exploit IRG proteins to create resistance mechanism against toxoplasma infection

One of the commonest parasites in the world is Toxoplasma gondii. Toxoplasma can infect most warm-blooded animals, including humans, and causes significant damage to the unborn child if a woman becomes infected for the first time during pregnancy.

30 Oct 2013

Researchers develop new substance that quickly and effectively kills multi-resistant bacteria

In Europe alone, more than 25,000 people die each year from infections caused by multi-resistant bacteria. Researchers from University of Copenhagen have now developed and characterized a substance that quickly and effectively kills the virulent bacteria. The substance employs a multifunctional mechanism that reduces the risk of antibiotic resistance. The findings have recently been published in the scientific journal Chemistry & Biology.

30 Oct 2013

Queen's University is lead partner in £6M global research program to develop new ways to treat CF

Queen's University Belfast is a lead partner in a new -6 million (euro) global research programme to develop new ways to treat Cystic Fibrosis.

30 Oct 2013

Physiological processes in soft tissue pain explored using PET imaging

Physiological processes in soft tissue pain such as chronic tennis elbow can be explored using diagnostic imaging methods. This is demonstrated by researchers from Uppsala University and the results are now being published in the prestigious journal PLOS ONE.

29 Oct 2013

EPFL and UNIL-CHUV scientists create first map of human HIV resistance

The key to future HIV treatment could be hidden right in our own genes. Everyone who becomes infected deploys defense strategies, and some even manage to hold the virus at bay without any therapy at all.

29 Oct 2013

Lipid secreted by tumors inhibits immune response against cancer

Researchers at National Jewish Health have discovered how a lipid secreted by cancer tumors prevents the immune system from mounting an immune response against it. When lysophosphatidic acid binds to killer T cells, it acts almost like an "invisibility cloak," preventing T cells from recognizing and attacking nascent tumors.

29 Oct 2013

Infants who get hepatitis C from mothers during childbirth may inherit viral strain

Infants who get hepatitis C from their mothers during childbirth may inherit a viral strain that replicates more quickly than strains found in non-pregnant hosts, according to a new study published Oct. 27 in Nature Medicine.

29 Oct 2013

High levels of omega-3 fatty acid consumption may lead to unintended health consequences

A new review suggests that omega-3 fatty acids taken in excess could have unintended health consequences in certain situations, and that dietary standards based on the best available evidence need to be established.

29 Oct 2013

Research findings could help define new vaccination applications

New research from the Masonic Cancer Center, University of Minnesota, and the University of Minnesota Center for Immunology has identified key proteins that influence immune response strategies, a finding that could influence new vaccination approaches.

29 Oct 2013

Immune System News and Research

Interaction between fat cells and bacterial toxins can lead to chronic inflammation

New finding could help lead to better treatments for eczema

Scientists unravel the major cause of protein citrullination in rheumatoid arthritis

Early stem cell transplants does not improve overall survival in non-Hodgkin's lymphoma patients

New insights into human cytomegalovirus may lead to development of therapeutic interventions

CytoDyn submits protocol to FDA for Phase IIb clinical trial of PRO 140

UofL researcher enters into license and research collaboration agreement with Novartis

Immune Design closes Series C financing totalling up to $49M

Researchers overcome obstacle to using viruses to deliver therapeutic genes

Promising melanoma drug demonstrates potential for non-small cell lung cancer treatment

New DNA vaccine effective against plaques in mouse model of Alzheimer's disease

Mice exploit IRG proteins to create resistance mechanism against toxoplasma infection

Researchers develop new substance that quickly and effectively kills multi-resistant bacteria

Queen's University is lead partner in £6M global research program to develop new ways to treat CF

Physiological processes in soft tissue pain explored using PET imaging

EPFL and UNIL-CHUV scientists create first map of human HIV resistance

Lipid secreted by tumors inhibits immune response against cancer

Infants who get hepatitis C from mothers during childbirth may inherit viral strain

High levels of omega-3 fatty acid consumption may lead to unintended health consequences

Research findings could help define new vaccination applications

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News